Monica Molteni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5262839/publications.pdf

Version: 2024-02-01

687363 839539 1,833 19 13 18 citations h-index g-index papers 19 19 19 3252 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature Medicine, 2010, 16, 413-419.	30.7	777
2	The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	295
3	Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiology of Disease, 2017, 99, 12-23.	4.4	149
4	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain, Behavior, and Immunity, 2017, 60, 188-197.	4.1	123
5	Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Letters, 2006, 235, 75-83.	7.2	95
6	Neurodegenerative diseases: The immunological perspective. Journal of Neuroimmunology, 2017, 313, 109-115.	2.3	76
7	A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. Journal of Experimental Medicine, 2006, 203, 1481-1492.	8.5	71
8	Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration. Molecular Medicine, 2012, 18, 971-981.	4.4	66
9	Natural Products with Toll-Like Receptor 4 Antagonist Activity. International Journal of Inflammation, 2018, 2018, 1-9.	1.5	47
10	Graves' Disease: A Host Defense Mechanism Gone Awry. International Reviews of Immunology, 2000, 19, 633-664.	3.3	31
11	A Cyanobacterial Lipopolysaccharide Antagonist Inhibits Cytokine Production Induced by (i>Neisseria meningitidis (i>in a Human Whole-Blood Model of Septicemia. Infection and Immunity, 2008, 76, 3156-3163.	2.2	24
12	Lipopolysaccharides in Cyanobacteria: A Brief Overview. Advances in Microbiology, 2016, 06, 391-397.	0.6	23
13	High Frequency of T-Cell Lines Responsive to Immunodominant Epitopes of Thyrotropin Receptor in Healthy Subjects. Thyroid, 1998, 8, 241-247.	4.5	14
14	The Effect of Cyanobacterial LPS Antagonist (CyP) on Cytokines and Micro-RNA Expression Induced by Porphyromonas gingivalis LPS. Toxins, 2018, 10, 290.	3.4	11
15	Regulatory CD8+ T cells control thyrotropin receptor-specific CD4+ clones in healthy subjects. Cancer Detection and Prevention, 2003, 27, 167-174.	2.1	10
16	Coadministration of the cyanobacterial lipopolysaccharide antagonist CyP with antibiotic inhibits cytokine production by an in vitro meningitis model infected with Neisseria meningitidis. Journal of Antimicrobial Chemotherapy, 2012, 67, 1145-1154.	3.0	9
17	MiR-146a induction by cyanobacterial lipopolysaccharide antagonist (CyP) mediates endotoxin cross-tolerance. Scientific Reports, 2018, 8, 11367.	3.3	9
18	Co-expression of the CD8 receptor in a human CD4+ T-cell clone influences proliferation, cytosolic Ca2+ release and cytokine production. Immunology Letters, 2002, 83, 111-117.	2.5	3

MONICA MOLTENI

#	Article	IF	CITATIONS
19	Toll-Like Receptor 4 and the World of microRNAs. Agents and Actions Supplements, 2021, , 143-157.	0.2	0